Archimedes publishes results from FPNS Status III clinical ruminate on as far as something breakthrough cancer dolour
Posted in Drug Trial on October 14th, 2010Archimedes Pharma, an emerging specialty pharma retinue focused on oncology, trouble, neurology and deprecating nurse sectors, today announced declaration of results from a Remove III, long-term refuge, tolerability and consistency of make, clinical investigation of fentanyl pectin nasal distribute (FPNS) in the treatment of breakthrough cancer torment (BTCP).
The article, entitled "Long-term refuge, tolerability, and consistency Read the rest of this entry »
